SHP2 inhibitor · small molecule
batoprotafib
1 active trials across 3 of our biomarkers, targeting SHP2. Not approved for any biomarker on marked.bio yet.
Also known as TNO155.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| KRAS G12C | 1 | 2 | Phase 1/2 |
| ALK fusion | 0 | 1 | – |
| BRAF V600E | 0 | 1 | – |
Sponsors
Industry sponsors leading active biomarker-selected trials of batoprotafib.
- Novartis 1
Trials
1 of 4 trials shown
-
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
opnurasibbatoprotafibtislelizumab
Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to…
KRAS G12CKRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
-
Lorlatinib Combinations in Lung Cancer
lorlatinib FDA EUcrizotinib FDA EUbinimetinibbatoprotafib
A Phase IB/II Study of Lorlatinib Combinations in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
ALK fusionLung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement, Relapsed Cancer
-
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
adagrasib FDA EUbatoprotafib
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
KRAS G12CAdvanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
-
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
dabrafenib FDA EULTT462trametinib FDA EUnaporafenibbatoprotafibspartalizumabtislelizumab
All patients must have a BRAF V600 mutation confirmed by local assessment.
BRAF V600EBRAF V600 Colorectal Cancer
No trials match these filters.